Clarity Pharmaceuticals Ltd   Report issue

For profit Phase 2 Phase 3
Founded: Sydney Australia (2010)

Organization Overview

First Clinical Trial
2015
NCT04440956
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Clarity Pharmaceuticals | Clarity Pharmaceuticals Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

64cu-sar-bispsma (4 trials)

Drugs in Phase 2 Trials (4)

64cu-sar-bbn (3 trials)

cu-64 sartate (1 trial)

cu-67 sartate (1 trial)

mecosar-tyr3-octreotate (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Meningioma (Phase 2)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5